investor update

Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025

Telomir Pharmaceuticals (NASDAQ: TELO) shares react to new preclinical leukemia data and a director resignation on November 21, 2025. Here’s what today’s Telomir-1 news means for TELO stock and investors. What happened to Telomir Pharmaceuticals (TELO) today? On Friday, November 21, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a Miami‑based preclinical biotech focused on small‑molecule therapies for cancer, aging and age‑related disease, released a new press release highlighting fresh in‑vitro data in human leukemia cells. FinanzNachrichten.de+1 In parallel, investors digested a separate corporate governance update: the company disclosed that board member Dr. Craig Eagle has stepped down, effective November 14, 2025,

21 November 2025

Opendoor (OPEN) today — Nov. 10, 2025: JPMorgan calls a ‘major transformation,’ while investors weigh a $1.2B note repurchase, 180.6M‑share sale, and a new tradable‑warrants dividend

Opendoor (OPEN) Pops as CEO Pledges $1M Share Purchase and Goldman Discloses 5.1% Stake — What Investors Need to Know Today (Nov. 11, 2025)

Date: November 11, 2025 Ticker: NASDAQ: OPEN At a Glance (Nov. 11) OPEN Stock Today: Price, Volume and Context By late session Tuesday, Opendoor traded near $8.48, up about 0.53 on the day, after ranging from $7.82 to $8.61. Turnover was intense, topping 224 million shares, underscoring how retail flows and headline risk continue to amplify intraday swings. U.S. equity markets were open for trading on Veterans Day (Nov. 11), though the bond market was closed — a nuance that sometimes affects liquidity and volatility profiles. CBS News What’s Driving Opendoor Today 1) CEO Share‑Buy Pledge New CEO Kaz Nejatian said in a Monday night post that today would be the first day he’s allowed

11 November 2025

CEO Insights · Company News · Financial Analysis · Investing · NASDAQ:OPEN · Stock Market